Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Repligen to Report First Quarter 2024 Financial Results
07:30am, Wednesday, 17'th Apr 2024
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET
Repligen Appoints Maggie A. Pax to Board of Directors
07:30am, Tuesday, 19'th Mar 2024
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This
PBYI vs. RGEN: Which Stock Is the Better Value Option?
12:46pm, Monday, 04'th Mar 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Puma Biotech (PBYI) and Repligen (RGEN). But which of these two companies is the best op
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
11:41am, Thursday, 22'nd Feb 2024
Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.
Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript
02:35pm, Wednesday, 21'st Feb 2024
Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
09:46am, Wednesday, 21'st Feb 2024
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.68 per share a year ago.
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
07:30am, Wednesday, 21'st Feb 2024
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
07:30am, Wednesday, 07'th Feb 2024
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Wednesday, 31'st Jan 2024
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
06:11am, Monday, 29'th Jan 2024
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
HRMY vs. RGEN: Which Stock Is the Better Value Option?
12:41pm, Monday, 22'nd Jan 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two st
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 19'th Dec 2023
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at th
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreem
Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 30'th Nov 2023
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report
02:01pm, Tuesday, 14'th Nov 2023
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of
